Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVEAL: NKTR-262 + Bempegaldesleukin +/- Nivolumab in Solid Tumors
NCT03435640Phase 2Terminated
- Sponsor
- Nektar Therapeutics
- Start
- Mar 2018
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of NKTR-262 in melanoma, Merkel cell carcinoma (MCC), triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), colorectal cancer (CRC), sponsored by Nektar Therapeutics. Started Mar 2018; status: terminated.
02
Drugs
NKTR-262
03
Conditions
melanomaMerkel cell carcinoma (MCC)triple-negative breast cancer (TNBC)renal cell carcinoma (RCC)colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT03435640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03435640.